ERBB2 and breast carcinoma: The other ER-positive lines were initially sensitive to L + T treatment, but later ER was used as an escape pathway to cause acquired resistance to L + T. Thus, in ER-positive/HER2-positive breast cancer cells, either ER or HER2 can function initially as the major promoter of proliferation and survival.